


Autoimmunity
Q&A with Dr. Oliver Brain: Unintended Consequences Create a Unique Opportunity to Study Inflammatory Bowel Disease.
Oliver Brain, MRCP, PhD, is a principal investigator at the University of Oxford, Nuffield Department of Clinical Medicine, and a recent winner of an nCounter® Autoimmune Profiling Panel through a…

Digital Spatial Profiling Q&A
Q&A with Dr. Sergio Rutella: Multi-analyte studies in acute myeloid leukemia
Sergio Rutella, M.D., Ph.D. FRCPath is a Professor of Cancer Immunotherapy at the John van Geest Cancer Research Centre at Nottingham Trent University. His research focuses on acute myeloid leukemia…

3D Biology™ Technology Q&A
Q&A with Dr. David Coffey, FHCRC: Multi-analyte studies in multiple myeloma and lymphoma
David Coffey, MD, is a physician scientist with the Fred Hutchinson Cancer Research Center in Seattle, Washington. When he’s not treating patients, he’s in the lab researching blood cancers such…

3D Biology™ Technology
Getting More from Flow Cytometry
Immunology studies rely on identifying unique cell populations, such as T cells and B cells, and then analyzing these cells to understand the biology of these cells. Studying different types…

3D Biology™ Technology Q&A
Multi-Analyte Analysis of Lung Cancer FFPE Samples with 3D Biology™ Technology
NanoString sat down with McGarry Houghton, M.D., Associate Member of the Clinical Research and Human Biology Divisions at Fred Hutch Cancer Research Center, to discuss how his lab is using…

3D Biology™ Technology
Researcher Profiles: How NanoString® Grant Program Winners are Utilizing 3D Biology™ Technology
This past February, four grant program applicants were awarded nCounter Vantage 3D™ Assays of their choice to profile 36 samples. NanoString followed up with each of the winners to explore…

Digital Spatial Profiling Q&A
Characterizing Severe Autoimmune Toxicities Associated with Checkpoint Inhibitor Therapies
Immune checkpoint inhibitors (ICI) have emerged as powerful tools against cancer but in some cases have caused inflammation of organ systems that contributed to morbidity or mortality in patients. The…

3D Biology™ Technology Q&A
Monitoring Clinically Actionable Proteins- A Q&A with Gordon Mills, MD Anderson Cancer Center
NanoString sat down with Gordon Mills, M.D., Ph.D., Chair of Systems Biology Department at MD Anderson Cancer Center in Houston and lead developer of The Cancer Proteome Atlas (TCPA), to…

Hyb & Seq™ Technology
Live sequencing with the Hyb & Seq™ platform at AGBT 2017
“We wanted to make the world’s simplest sequencer,” remarked Joe Beechem, Ph.D., Senior Vice President of R&D at NanoString. Beechem presented the Hyb & Seq platform with live demonstration during…